The Science Behind Stem Cell Therapy: Research Review and Future Prospects (2026)

By

Scientific Review by the Clinical Editorial Team  |  Published: November 2019  |  Last Reviewed: July 2026  |  Category: Regenerative Medicine | Evidence Review

Quick Answer

Stem cell research has grown to over 379,000 published studies on PubMed as of mid-2026, but the evidence is not uniform across conditions. Hematopoietic stem cell transplantation for leukemia and lymphoma is decades-old, FDA-licensed standard of care. A donor islet cell therapy, Lantidra, became the first FDA-approved cellular therapy for type 1 diabetes in 2023, and a stem-cell-derived successor, zimislecel, is now in Phase 3 trials. Everything else on this page — stroke, osteoarthritis, spinal cord injury, autoimmune disease, heart disease, autism, anti-aging, hair loss, kidney and liver disease, and back pain — remains investigational, with no FDA-approved stem cell product for these indications. The FDA has repeatedly warned that clinics marketing unapproved stem cell and exosome products for these exact conditions put patients at risk of serious harm.

Introduction

Trying to keep up with stem cell therapy evidence is genuinely difficult. As of mid-2026, PubMed indexes more than 379,000 scientific publications containing the term "stem cell," with over 26,000 published in 2025 alone and more than 15,000 already in the first half of 2026. The field has roughly doubled in output since this article's original 2019 compilation.

Legacy dataset (1946–2020) shown for historical context. Publication volume has continued to climb sharply since; see the updated, per-condition figures below.

Stem cell therapy has gained popularity as a treatment option where standard protocols have been exhausted, but it is also one of the most heavily marketed and least well-regulated corners of medicine. This update separates what is genuinely established from what remains experimental, using current PubMed and ClinicalTrials.gov data and the FDA's own regulatory guidance.

How We Grade the Evidence

Each condition below is tagged with an evidence tier, adapted from the Oxford Centre for Evidence-Based Medicine (CEBM) hierarchy, to separate marketing claims from clinical reality:

Tier 1 Established standard of care — supported by systematic reviews/RCTs and FDA-licensed or guideline-endorsed.
Tier 2 Promising, multiple controlled trials — not yet standard of care or FDA-approved for this indication.
Tier 3 Early-phase clinical (Phase 1/2) — safety and signal data only, efficacy unconfirmed.
Tier 4 Preclinical or small/uncontrolled human data — mechanistically plausible, clinically unproven.
Tier 5 Unproven / directly marketed to consumers — the FDA has specifically flagged this use in enforcement actions.

FDA Regulatory Status: What's Actually Approved

⚠ Regulatory Reality Check

As of 2026, the FDA confirms that the only stem cell products approved for general use in the United States are blood-forming (hematopoietic) stem cells derived from umbilical cord blood, used for disorders of blood and immune cell production. Everything else — adipose-derived cells, cultured or expanded mesenchymal stem cells, amniotic fluid products, exosomes, and umbilical cord tissue products used for non-blood conditions — requires an active FDA investigational new drug application and has not been approved for general marketing.

The FDA has documented adverse events from unapproved products including infections, tumor formation, and blindness, and has issued hundreds of warning letters to clinics and manufacturers since 2018, including a 2026 wave of letters targeting unapproved exosome products specifically. Regulators have also named specific conditions repeatedly targeted by unapproved marketing, including orthopedic pain, autism, Parkinson's disease, and stroke.

One narrow exception exists in diabetes: Lantidra (donislecel), a donor-derived (not stem-cell-derived) pancreatic islet cell therapy, received full FDA approval in June 2023 for adults with type 1 diabetes and severe, hard-to-manage hypoglycemia. See the diabetes section below for what this does and does not mean for the broader field.

If you are evaluating a stem cell clinic anywhere in the world, ask directly: what is the regulatory status of this specific product, in this specific country, for this specific condition? A clinic that cannot answer clearly, or that points only to a clinicaltrials.gov listing as proof of approval, is a red flag the FDA itself has called out.

Evidence at a Glance

Condition Evidence Tier FDA Status PubMed Studies
LeukemiaTier 1Licensed (HSCT)41,000+
Non-Hodgkin LymphomaTier 1Licensed (HSCT)14,000+
Diabetes (Type 1)Tier 1 / Tier 3Lantidra approved; zimislecel Phase 33,000+
OsteoarthritisTier 2Not approved~2,950
Back Pain / DDDTier 2–3Not approved280+
Autoimmune DiseaseTier 2–3Not licensed for this use900+
StrokeTier 3Not approved3,000+
Spinal Cord InjuryTier 3Not approved2,000+
Liver DiseaseTier 3Not approved900+
Kidney DiseaseTier 3Not approved650+
Heart Disease / FailureTier 3–4Not approved1,500+
Hair LossTier 3–4Not approved100+
Anti-AgingTier 4–5Not approved200+
AutismTier 5Not approved; FDA-flagged~1,116

1. Leukemia

TIER 1 — ESTABLISHED STANDARD OF CARE

Leukemia affects the bone marrow and lymphatic system; it is the most common childhood cancer but occurs across all ages. Allogeneic and autologous hematopoietic stem cell transplantation (HSCT) — high-dose chemotherapy (sometimes with radiation) followed by an infusion of stem cells to repopulate healthy blood cells — is standard post-remission therapy for eligible relapsed and high-risk patients, and is one of the few stem cell applications with genuine FDA licensure and decades of trial evidence behind it.

There are now more than 41,000 publications on stem cells and leukemia (2,317 in 2025 alone), and you can review the current status of active trials on ClinicalTrials.gov. With transplantation during first remission, five-year survival runs roughly 30–50%; patients who avoid relapse within two years of transplant have a good chance of long-term survival.

2. Non-Hodgkin's Lymphoma

TIER 1 — ESTABLISHED STANDARD OF CARE

Non-Hodgkin's lymphoma arises in the lymphatic system and is almost universally fatal without treatment. High-dose chemotherapy is highly effective against the cancer but destroys the bone marrow's ability to make new blood cells. Autologous stem cell transplantation lets patients tolerate these curative-intent doses by restoring blood cell production afterward.

There are more than 14,000 publications on stem cells and lymphoma, and active trials are tracked on ClinicalTrials.gov.

3. Stem Cell Therapy for Stroke

TIER 3 — EARLY-PHASE CLINICAL

Stroke is the world's second leading cause of death, and stem cell therapy has been explored as a supplemental strategy for decades, with more than 3,000 publications to date. A review published in Nature mapped clinical trial trends in stroke cell therapy using ClinicalTrials.gov and the International Clinical Trials Registry Platform, finding the field has reached early translational stages with human trial data emerging.

Individual patient stories, such as widely reported cases of stroke survivors regaining movement after experimental stem cell infusion, are sometimes cited as evidence. These accounts are worth noting but sit at the bottom of the evidence hierarchy — a single case report cannot establish that a therapy works, only that it may be worth studying in controlled trials. No stem cell product is FDA-approved for stroke; current trials remain Phase 1/2. Track ongoing studies on ClinicalTrials.gov.

4. Stem Cell Therapy for Osteoarthritis

TIER 2 — PROMISING, NOT YET STANDARD OF CARE

Osteoarthritis is the progressive breakdown of joint cartilage, most often affecting the knees, hips, and hands. The evidence base has grown to nearly 3,000 publications (up from roughly 1,700 in 2019), with 425 published in 2025 — the field's busiest year yet. There are over 120 registered trials under the U.S. clinical trial registry.

Multiple comparative and randomized studies show measurable improvements in pain and function, particularly for knee osteoarthritis using adipose- or bone marrow-derived mesenchymal stem cells (MSCs). However, protocols vary widely between clinics — cell source, processing method, dose, and delivery all differ — and no product has been FDA-approved for this indication. Most clinics operating in the United States position their offerings as minimally manipulated, same-day procedures to fall within a narrower regulatory exemption; whether a specific clinic's product actually qualifies is not something patients can verify without documentation, which is why the regulatory status check above matters before proceeding with any orthopedic stem cell procedure.

5. Stem Cell Therapy for Diabetes Mellitus

TIER 1 (Lantidra)  TIER 3 (zimislecel)

This is the fastest-moving area of the entire field since our original compilation. There are more than 3,000 publications on stem cells and diabetes, and over 130 registered trials on ClinicalTrials.gov.

Lantidra (donislecel) — the first FDA-approved cellular therapy for type 1 diabetes

In June 2023, the FDA approved Lantidra, an allogeneic pancreatic islet cell therapy made from deceased-donor cells, for adults with type 1 diabetes who cannot reach target blood sugar control because of recurrent severe hypoglycemia despite optimized management. Note: Lantidra's islets come from human donors, not from stem cells — it is included here because it represents the first-ever full regulatory approval of any cellular replacement therapy for diabetes and reshapes what patients should expect the field to look like going forward. Patients require lifelong immunosuppression, and the therapy is reserved for a narrow, high-risk group.

Zimislecel (VX-880) — a true stem-cell-derived islet therapy, Phase 3

Vertex Pharmaceuticals' zimislecel is an investigational, allogeneic, stem-cell-derived islet cell therapy now in the Phase 3 portion of a Phase 1/2/3 trial, with global regulatory submissions expected in 2026. Phase 1/2 results published in the New England Journal of Medicine showed that participants with severe hypoglycemia unawareness achieved restored insulin production after a single infusion, with meaningful reductions in hypoglycemic events; all participants still required ongoing immunosuppression, and two unrelated deaths were reported in the trial. If approved, it would be the second cell therapy for type 1 diabetes and the first derived from stem cells rather than donor tissue — addressing the donor-supply bottleneck that limits Lantidra.

Outside of these two developments, most diabetes-related stem cell offerings marketed directly to consumers — including many DTC clinics claiming to "reverse" Type 2 diabetes — remain unapproved and unproven; they should not be confused with the regulated therapies above.

6. Stem Cell Therapy for Spinal Cord Injury

TIER 3 — EARLY-PHASE CLINICAL

Spinal cord injury has historically been irreparable; modern neurosurgery restores some function, but outcomes remain limited. Stem cells are being explored to replace, rather than repair, damaged neural tissue at the injury site. There are more than 2,000 publications and over 60 registered trials investigating this approach, most in Phase 1/2. No product is FDA-approved for spinal cord injury.

Related: Stem Cells and Spinal Cord Injury

7. Autoimmune Diseases

TIER 2–3 — VARIES BY CONDITION

Autoimmune conditions — including type 1 diabetes, rheumatoid arthritis, multiple sclerosis, lupus, and others — share a misdirected immune response against the body's own tissue. Stem cells are being studied both to repair damaged tissue and to modulate (reset) the immune response itself. There are more than 900 publications and over 200 registered trials.

The strongest evidence in this category is for autologous HSCT in aggressive, treatment-refractory relapsing multiple sclerosis, where controlled trial data support its use in carefully selected patients under specialist care — though it remains a significant, immunosuppressive procedure reserved for specific circumstances rather than a routine or FDA-labeled MS treatment. Evidence for stem cell approaches in lupus and other autoimmune conditions is earlier-stage.

8. Heart Disease and Heart Failure

TIER 3–4 — MIXED RESULTS, EARLY-PHASE

Heart disease remains a leading cause of death worldwide, and stem cells have long been explored as a way to repair or replace damaged heart tissue without surgery. There are more than 1,500 publications and over 200 registered trials.

Results across cardiac cell therapy trials have been genuinely mixed — some early trials showed modest functional benefit, while several larger, more rigorous trials have failed to replicate earlier promise. One notable regulatory milestone: in 2018, Japan's health ministry authorized a very limited, conditional trial of induced pluripotent stem cell-derived tissue sheets for heart repair at Osaka University, under Japan's distinct conditional approval pathway for regenerative medicine — this is not equivalent to FDA approval and applied to a handful of patients. No cardiac stem cell product is FDA-approved.

9. Stem Cell Therapy for Autism

TIER 5 — UNPROVEN, FDA-FLAGGED

Regulatory note: Autism is one of the specific conditions the FDA has named in enforcement actions against clinics marketing unapproved stem cell products. No stem cell product is approved for autism anywhere in mainstream regulated medicine, and parents should treat any clinic offering one as operating outside FDA oversight.

Stem cell therapy for autism is an active research topic but remains considered experimental by mainstream medicine. There are now more than 1,100 publications (up from roughly 600 in 2019) and around 20 registered trials. A 2026 single-center, double-blinded, randomized, placebo-controlled trial examined umbilical cord blood mononuclear cells for children with autism spectrum disorder and immune dysregulation — a genuinely rigorous study design worth watching, but a single trial does not establish an approved or proven treatment. Families should be especially cautious of fee-for-service clinics operating without FDA oversight and promoting individualized, unstandardized protocols.

10. Stem Cell Therapy for Anti-Aging

TIER 4–5 — PRELIMINARY / HEAVILY MARKETED

There are more than 200 publications on stem cells and anti-aging, though registered trials remain few. Two small studies published in The Journals of Gerontology found that allogeneic mesenchymal stem cell infusions were associated with improved quality-of-life measures and reduced inflammatory markers in frail older adults, including one placebo-controlled trial. These are encouraging pilot signals, not proof of an anti-aging effect, and no product is FDA-approved for this use. This is also one of the categories most heavily marketed direct-to-consumer, so apply the same regulatory-status check described above before considering any anti-aging stem cell offering.

11. Stem Cell Hair Treatment

TIER 3–4 — EARLY CLINICAL

Mesenchymal stem cells have emerged as a therapeutic option under study for hair loss, with more than 100 publications and roughly 10 registered trials. A small 2017 study from researchers at Rome University reported improved hair density at 23 weeks post-treatment. No product is FDA-approved for hair restoration via stem cells, and claims of restoring natural hair color specifically remain unproven beyond preliminary reports.

12. Stem Cell Therapy for Kidney Diseases

TIER 3 — EARLY-PHASE, SAFETY ESTABLISHED

There are more than 650 published studies on stem cells and kidney disease, and over 100 registered trials. Several clinical trials have confirmed the safety and tolerability of MSC-based therapies in patients with renal disease and kidney transplants, though efficacy data for disease-modifying benefit remain preliminary. No product is FDA-approved for kidney disease.

13. Stem Cell Therapy for Liver Diseases

TIER 3 — EARLY-PHASE, PROMISING

Liver failure from cirrhosis — due to chronic hepatitis B, non-alcoholic fatty liver disease, and other causes — was long thought irreversible outside of transplantation, and not every patient qualifies for a liver transplant, particularly given donor shortages in Malaysia. There are more than 900 published studies and over 90 registered trials. A systematic review of 37 studies by Malaysian researchers found both autologous and allogeneic adult stem cell-based therapies showed promising results restoring liver function in cirrhosis patients — encouraging, but not yet sufficient for regulatory approval.

14. Stem Cell Therapy for Back Pain

TIER 2–3 — PROMISING, NOT YET STANDARD OF CARE

Back pain has many causes, of which degenerative disc disease (DDD) is only one — an accurate diagnosis should always come before considering treatment. There are more than 280 published studies on stem cells and back pain.

In a landmark study by Pettine's group (2016), 26 patients with lumbar disc-related back pain who received bone-marrow-derived stem cell injections avoided surgery in 81% of cases at two years, with a 71% reduction in pain and 64% improvement in function; 40% showed improvement on follow-up MRI, with no reported complications. A 2016 registry study following 2,372 patients who received stem cell injections in various joints over 2.2 years reported no serious side effects. A 2018 meta-analysis concluded that cell-based therapy is associated with improved pain relief and disability scores for discogenic low back pain specifically.

There are more than 10 registered trials for stem cell therapy and back pain in the U.S. registry. Notable programs include four FDA-authorized adipose-derived stem cell trials at Sanford Health (knee and wrist osteoarthritis, rotator cuff tear, facet joints), Mesoblast's Phase 3 program for degenerative disc disease, and the EU-funded iPSpine consortium developing an advanced-therapy medicinal product for intervertebral disc regeneration. None of these are yet FDA-approved consumer products; small pre-clinical and clinical study sizes mean more definitive trial data is still needed.

15. Stem Cell Therapy for Other Indications

You can search the full database of NIH-sponsored trials at ClinicalTrials.gov using terms like "Parkinson's disease and stem cells" for any condition not covered above.

If you know of major stem cell research we've missed, let us know in the comments and we'll review it for inclusion.

Frequently Asked Questions

Is stem cell therapy FDA-approved?

Only hematopoietic (blood-forming) stem cells from cord blood, and Lantidra, a donor islet cell therapy for a narrow group of type 1 diabetes patients, are FDA-approved as of 2026. Nearly everything else marketed as stem cell therapy is not.

Which stem cell treatments have the strongest evidence?

Hematopoietic stem cell transplantation for leukemia and lymphoma, and autologous HSCT for aggressive relapsing multiple sclerosis, have the strongest trial-level support. Most other applications remain in earlier research phases.

Is stem cell therapy safe?

Regulated HSCT has well-characterized, medically supervised risks. Unregulated products sold directly to consumers carry additional documented risks, including infection, tumor formation, and blindness, per FDA safety communications.

Can stem cells treat autism?

No stem cell product is FDA-approved for autism, and the FDA has specifically flagged autism among conditions targeted by unapproved marketing. Research, including a 2026 randomized trial of umbilical cord blood cells, is ongoing but investigational.

What is the difference between stem cells and exosomes?

Stem cells are living, self-renewing cells. Exosomes are cell-derived vesicles, not cells. The FDA regulates exosome products as biologics requiring approval, and issued multiple 2026 warning letters over unapproved exosome marketing.

How many studies exist on stem cell therapy?

Over 379,000 on PubMed as of mid-2026, with more than 26,000 published in 2025 alone — though coverage varies enormously by condition.

Is stem cell therapy legal in Malaysia and Singapore?

Cellular products in Malaysia are regulated by the NPRA under the Ministry of Health; in Singapore, by the Health Sciences Authority. Ask any clinic for documentation of product registration before proceeding.

What new diabetes stem cell treatment is closest to approval?

Zimislecel (VX-880) from Vertex Pharmaceuticals, a stem-cell-derived islet therapy, is in Phase 3 trials with regulatory submissions expected in 2026.

Using AI Tools to Research Stem Cell Therapy

If you're asking Claude, ChatGPT, Gemini, or Perplexity about stem cell therapy for a specific condition, get sharper answers by asking directly for the evidence tier and current FDA status — not just "does it work." Useful prompts:

  • "What is the FDA regulatory status of stem cell therapy for [my condition] in 2026?"
  • "How many randomized controlled trials exist for [my condition], and what were the results?"
  • "What questions should I ask a stem cell clinic before treatment?"

Because this field moves quickly and is heavily marketed, prefer AI answers that cite primary sources (PubMed, ClinicalTrials.gov, FDA.gov) over general summaries, and always verify a specific clinic's claims independently before booking treatment.

Medical Disclaimer: This article is for general educational purposes only and does not constitute medical advice, diagnosis, or a treatment recommendation. Stem cell and cellular therapies outside of FDA-approved indications are investigational; discuss any treatment decision with a qualified physician and independently verify the regulatory status of any product or clinic before proceeding. One Day MD does not operate, endorse, or receive compensation from any stem cell clinic named or linked in this article.

Sources: U.S. National Library of Medicine (PubMed), ClinicalTrials.gov, U.S. Food and Drug Administration (FDA.gov), New England Journal of Medicine, Nature, and peer-reviewed journals linked inline above.

Last reviewed and updated: July 2026.

Comments

Post a Comment